

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

NDC	Lot	Exp. Date	Bottle Size
0555-0808-02	100022970	08/2022	100 Count

Teva Pharmaceuticals USA Inc. (Teva USA) is recalling the above referenced lot of **Tretinoin Capsules 10 mg** to the **Retail Level**. The affected product lot was distributed under the label of Teva Pharmaceuticals USA Inc. This recall has been initiated because the assay dissolution results for the specified lot are below specification limit at 13-months from date of manufacture. It should be noted that at the time of product release of this lot, all test results, including assay, were within specification limits. Tretinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. The main safety concern that may arise from the low capsule dissolution is decreased efficacy of the product due to lower bioavailability that may result in an exacerbation of the underlying disease and progression of APL. Nevertheless, to date, Teva has not received reports of adverse events or product complaints for the lot in this recall.